Kaitlyn J Kelly1, Joyce Wong, Yuman Fong. 1. Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Avenue, New York, NY 10065, USA.
Abstract
BACKGROUND: Patients with hepatic malignancy have a dismal prognosis with standard therapies. NV1020 is an oncolytic herpes simplex virus that has potential to be a safe and effective therapeutic agent for this disease. OBJECTIVE: We set out to discuss the development of NV1020 as an oncolytic agent and explore the potential role of this particular virus in the setting of human hepatic cancer. METHODS: The scope of this review includes an overview of preclinical experience with NV1020, as well as an examination of current standard and developing therapies for liver cancer. The primary focus, however, is on the safety and potential clinical efficacy of NV1020 against hepatic malignancy. RESULTS/ CONCLUSION: We have found that NV1020 is a safe, novel therapeutic agent for treatment of refractory hepatic malignancy.
BACKGROUND:Patients with hepatic malignancy have a dismal prognosis with standard therapies. NV1020 is an oncolytic herpes simplex virus that has potential to be a safe and effective therapeutic agent for this disease. OBJECTIVE: We set out to discuss the development of NV1020 as an oncolytic agent and explore the potential role of this particular virus in the setting of humanhepatic cancer. METHODS: The scope of this review includes an overview of preclinical experience with NV1020, as well as an examination of current standard and developing therapies for liver cancer. The primary focus, however, is on the safety and potential clinical efficacy of NV1020 against hepatic malignancy. RESULTS/ CONCLUSION: We have found that NV1020 is a safe, novel therapeutic agent for treatment of refractory hepatic malignancy.
Authors: James M Markert; Jacqueline N Parker; Donald J Buchsbaum; William E Grizzle; G Yancey Gillespie; Richard J Whitley Journal: Herpes Date: 2006-11
Authors: Nancy Kemeny; Karen Brown; Anne Covey; Teresa Kim; Amit Bhargava; Lynn Brody; Brenda Guilfoyle; Natasha P Haag; Matthias Karrasch; Birgit Glasschroeder; Anette Knoll; George Getrajdman; K Jon Kowal; William R Jarnagin; Yuman Fong Journal: Hum Gene Ther Date: 2006-12 Impact factor: 5.695
Authors: Jennifer C Hu; Matthew J Booth; Gopichand Tripuraneni; Derek Davies; Syed A A Zaidi; Manuela Tamburo de Bella; Martin J Slade; Stephen B Marley; Myrtle Y A Gordon; Robert S Coffin; R Charles Coombes; Tahereh Kamalati Journal: Clin Cancer Res Date: 2006-11-15 Impact factor: 12.531
Authors: Yonatan Y Mahller; Sachin S Vaikunth; Mark A Currier; Shyra J Miller; Maria C Ripberger; Ya-Hsuan Hsu; Ruty Mehrian-Shai; Margaret H Collins; Timothy M Crombleholme; Nancy Ratner; Timothy P Cripe Journal: Mol Ther Date: 2007-02 Impact factor: 11.454
Authors: Zhenkun Yu; Prasad S Adusumilli; David P Eisenberg; Elizabeth Darr; Ronald A Ghossein; Sen Li; Shiquan Liu; Bhuvanesh Singh; Jatin P Shah; Yuman Fong; Richard J Wong Journal: Mol Ther Date: 2007-01 Impact factor: 11.454
Authors: A Nakao; S Takeda; S Shimoyama; H Kasuya; H Kimata; O Teshigahara; M Sawaki; T Kikumori; Y Kodera; T Nagasaka; F Goshima; Y Nishiyama; T Imai Journal: Curr Cancer Drug Targets Date: 2007-03 Impact factor: 3.428
Authors: Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik Journal: Hum Gene Ther Date: 2010-09 Impact factor: 5.695